NASH Drug Cost Concerns On Level With HCV Treatments For Payers
This article was originally published in The Pink Sheet Daily
Executive Summary
OptumRx, Harvard Pilgrim watching closely as Intercept’s Ocaliva nears market entry with claim for primary biliary cholangitis; use restrictions against off-label use in NASH are likely.